No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples